View Older Stories View More Recent Stories

Aug 9, 2016 01:09AM ABLYNX REPORTS COMPELLING TOPLINE PHASE IIb STUDY RESULTS WITH ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, IN RA PATIENTS, CONFIRMING ITS BEST-IN-CLASS POTENTIAL
Aug 4, 2016 01:11AM BANK OF AMERICA CORPORATION ANNOUNCE 5.24% SHAREHOLDING IN ABLYNX
Jul 20, 2016 01:08AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 7, 2016 01:08AM ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA
Jun 16, 2016 12:12PM CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX
Jun 16, 2016 01:08AM VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX
Jun 14, 2016 01:12AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jun 10, 2016 12:07PM PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jun 3, 2016 01:06AM ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES HEALTHCARE CONFERENCE 2016
May 26, 2016 01:24AM ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACIZUMAB IN ACQUIRED TTP PATIENTS AT THE 21st CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
May 13, 2016 01:04AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
May 12, 2016 01:06AM ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE
May 3, 2016 01:11AM ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS HOSPITALISED WITH AN RSV INFECTION
Apr 29, 2016 01:04AM ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION
Apr 22, 2016 01:06AM ABLYNX ANNOUNCES WARRANT EXERCISE
Apr 21, 2016 01:05AM ABLYNX TO RECEIVE AN EU8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS A PHASE I STUDY WITH AN ANTI-CX3CR1 NANOBODY
Mar 22, 2016 02:08AM ABLYNX ANNOUNCES WARRANT EXERCISE
Mar 14, 2016 02:10AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Mar 7, 2016 01:04AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Feb 25, 2016 01:09AM ABLYNX ANNOUNCES 2015 FULL YEAR RESULTS
Feb 23, 2016 01:09AM ABLYNX ANNOUNCES WARRANT EXERCISE
Feb 18, 2016 01:11AM ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016
Feb 11, 2016 01:17AM NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ABLYNX'S PHASE II TITAN STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP
Jan 29, 2016 01:06AM ABLYNX TO RECEIVE EU8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY
Jan 21, 2016 01:05AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jan 18, 2016 01:19AM PERCEPTIVE ADVISORS LLC ANNOUNCE 5.06% SHAREHOLDING IN ABLYNX
Jan 7, 2016 01:04AM ABLYNX TO PRESENT AT THE 34th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Jan 5, 2016 01:07AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Dec 22, 2015 01:10AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Dec 17, 2015 01:05AM ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS
Dec 16, 2015 12:13PM ABLYNX ANNOUNCES WARRANT EXERCISE
Dec 9, 2015 01:07AM ABLYNX ANNOUNCES WARRANT EXERCISE
Dec 2, 2015 01:04AM JP MORGAN ASSET MANAGEMENT HOLDINGS ANNOUNCE 3.33% SHAREHOLDING IN ABLYNX
Dec 1, 2015 01:05AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Nov 30, 2015 01:14AM ABLYNX APPOINTS ROBERT K. ZELDIN, MD, CHIEF MEDICAL OFFICER
Nov 25, 2015 01:06AM ABLYNX ANNOUNCES NANOBODY DRUG DISCOVERY COLLABORATION WITH NOVO NORDISK
Nov 18, 2015 01:08AM ABLYNX PROVIDES BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2015
Nov 5, 2015 01:05AM ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EURO GLOBAL SUMMIT ON CANCER THERAPY
Oct 21, 2015 01:08AM ABLYNX ANNOUNCES WARRANT EXERCISE
Oct 15, 2015 01:09AM ABLYNX ACHIEVES FIRST MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.
Sep 29, 2015 01:04AM ABLYNX INITIATES A MULTINATIONAL PHASE III STUDY WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP, A RARE BLOOD CLOTTING DISORDER
Aug 27, 2015 01:06AM ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015
Aug 19, 2015 01:04AM ABLYNX TO HOST WEBCAST FOR ITS 2015 HALF-YEAR RESULTS ON 27 AUGUST
Aug 14, 2015 01:10AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Aug 4, 2015 01:06AM ABLYNX INITIATES PHASE II SLE STUDY WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE
Jul 31, 2015 01:05AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 29, 2015 01:05AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jul 22, 2015 01:08AM ABLYNX SIGNIFICANTLY EXPANDS ITS IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.
Jul 20, 2015 01:04AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 14, 2015 01:11AM OPPENHEIMER FUNDS, INC. ANNOUNCE 3.07% SHAREHOLDING IN ABLYNX
View More Recent Stories View Older Stories